According to the nomenclature established by the World Health Organization (WHO) to devise international non-proprietary names (INNs), the INNs of gonadorelin (gonadotrophin-releasing hormone or GnRH) antagonists end in the common stem -relix (1). Three drugs with this stem were marketed in France as of 22 November 2017: degarelix for prostate cancers; and cetrorelix and ganirelixto prevent premature ovu-lation in assisted reproduction protocols (2).This stem should not be confused with the stem -relin, used for peptides that stimulate the release of pituitary hormones, such as triptorelin or leuprorelin, which are gonadorelin agonists (3).
展开▼
